Lisata Therapeutics

LSTA

Market cap $21.4M

Basking Ridge, New Jersey--(Newsfile Corp. - October 13, 2025) -  Lisata Therapeutics, Inc. (NASDAQ: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D.

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's new collaboration with Catalent, which reinforces its strategy to leverage the broad applicability of its lead molecule, certepetide, across multiple cancer types and treatment modalities. Proactive: Hello, you're watching Proactive.

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a global product license agreement with Catalent Inc, which would allow Catalent to incorporate Lisata's certepetide into antibody-drug conjugates (ADCs) developed using Catalent's SMARTag technology platform.  The clinical-stage pharmaceutical company said Certepetide, a proprietary, internalizing RGD (arginyl-glycyl-aspartic acid), or “iRGD” cyclic peptide, is being tested by Lisata as a cancer therapeutic to be used in combination with other anti-cancer agents to enhance tumor targeting and penetration and improve treatment outcomes.

Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases

Lisata Therapeutics Inc (NASDAQ:LSTA) announced what it called “encouraging” preliminary data from the pancreatic ductal adenocarcinoma (PDAC) cohort of the Phase 1/2a CENDIFOX trial.  The clinical-stage pharmaceutical company said the investigator-initiated trial is evaluating Lisata's proprietary investigational iRGD cyclic peptide product candidate, certepetide, in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers.

Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions

BASKING RIDGE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J.

Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David J. Mazzo - President, CEO & Director James Nisco - Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen K.

Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it is making steady progress in advancing its pipeline of oncology drug candidates, with several key clinical trial readouts anticipated through the remainder of 2025 and into 2026. The company reaffirmed its financial runway into the fourth quarter of next year, positioning it to continue developing certepetide, its lead investigational therapy for advanced solid tumors.

Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone